CAIN2401 safeguard
Study details
Study purpose: RCT with placebo- controlled withdrawal- retreatment period of secukinumab in no-axSpA
Symptoms/Diagnose: NR-axiale SpA
Disease phase: Active no- axSpA
Indication/Medication: Biological-naïve nr- axSpA patients with indication for starting biologicals
In short
Key points
SpA and pre-SpADiseases
SpondylarthritisCommitted staff members
Contact us
s.groothuizen@amsterdamumc.nlMore studies
3TR - Flare study
Research on biomarkers for developing a flare in SLE
- SLE
- Systemic Lupus Erythematosus
- Broens, B. (Bo)
IgG4 in vasculitis
IgG4/IgG RNA ratio as a disease activity marker in vasculitis
- General
- Vasculitis
- Weele, L. van der (Linda)
FaMaLE
Study of failing immune tolerance between mother and fetus as cause of pregnancy complications in SLE
- SLE
- Systemic Lupus Erythematosus
- Dankers, W. (Wendy)
JAKARTA
Evaluation effect of Filgotinib on heart through cardiac MRI/CT in RA
- RA and pre-RA
- Rheumatoid arthritis
- Bas Dijkshoorn
Onderzoek not found.
PsA BIOnd
Observational cohort study of Guselkumab (Tremfya) and anti- IL17 therapy in PSA
- SpA and pre-SpA
- Spondylarthritis
- Groothuizen, S. (Sam)
PO Box 7057
1007 MB Amsterdam
The Netherlands